{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:20:06Z","timestamp":1781713206272,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There are no randomized control trials comparing the efficacy of trifluridine\/tipiracil and regorafenib in patients with metastatic colorectal cancer (mCRC). Herein, we conducted an observational study to compare the oncologic outcomes of trifluridine\/tipiracil-containing regimen (TAS-102) and regorafenib-containing regimen (REG) in patients with mCRC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and method<\/jats:title><jats:p>Patients who were diagnosed to have mCRC in 2015 to 2021 and treated with TAS-102-containing regimen or REG-containing regimen were recruited. Monotherapy or combination therapy were all allowed in this study. Oncologic outcomes were presented with progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and disease control rate (DCR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 125 patients were enrolled into our study, accounting for 50 patients with TAS-102 and 75 patients with REG. Of these patients, 64% were treated with TAS-102 or REG monotherapy, while the remaining were treated with TAS-102 combination or REG combination. In general, the median PFS and OS were 3.7 versus 2.0 months (<jats:italic>P<\/jats:italic> = 0.006) and 9.2 versus 6.8 months (<jats:italic>P<\/jats:italic> = 0.048) in TAS-102 and REG, respectively. The ORR and DCR were 44% versus 20% (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) and 72% versus 43% (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) in TAS-102 and REG, respectively. As for treatment strategies, the survival were significantly longer in combination than in monotherapy, no matter in TAS-102 or REG group. Multivariate analysis showed TAS-102 and combination therapy were independent predictor associated with better survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results suggested that TAS-102 had better oncologic outcomes than REG in patients with mCRC, especially in combination. Further prospective trials are warranted to confirm our results.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.867546","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:20:44Z","timestamp":1652937644000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["An Observational Study of Trifluridine\/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Meng-Che","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Ming","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shung-Eing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Chi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-I","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Chiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Pao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21601","article-title":"Colorectal Cancer Statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3487","article-title":"Repeated Oral Dosing of TAS-102 Confers High Trifluridine Incorporation Into DNA and Sustained Antitumor Activity in Mouse Models","volume":"32","author":"Tanaka","year":"2014","journal-title":"Oncol Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): A New Oral Multikinase Inhibitor of Angiogenic, Stromal and Oncogenic Receptor Tyrosine Kinases With Potent Preclinical Antitumor Activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2020.05.003","article-title":"Effectiveness and Safety of Regorafenib vs. Trifluridine\/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study","volume":"19","author":"Nakashima","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.07.019","article-title":"Regorafenib Versus Trifluridine\/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison","volume":"16","author":"Masuishi","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234314","article-title":"Regorafenib vs Trifluridine\/Tipiracil for Metastatic Colorectal Cancer Refractory to Standard Chemotherapies: A Multicenter Retrospective Comparison Study in Japan","volume":"15","author":"Ogata","year":"2020","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30425-4","article-title":"TAS-102 Plus Bevacizumab for Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies (C-TASK FORCE): An Investigator-Initiated, Open-Label, Single-Arm, Multicentre, Phase 1\/2 Study","volume":"18","author":"Kuboki","year":"2017","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000605","article-title":"Chemotherapy Plus Bevacizumab as an Optimal First-Line Therapeutic Treatment for Patients With Right-Sided Metastatic Colon Cancer: A Meta-Analysis of First-Line Clinical Trials","volume":"4","author":"You","year":"2020","journal-title":"ESMO Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and Predictive Value of Primary Tumour Side in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With Chemotherapy and EGFR Directed Antibodies in Six Randomized Trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3630","article-title":"A Phase 2 Trial of Trifluridine\/Tipiracil Plus Nivolumab in Patients With Heavily Pretreated Microsatellite-Stable Metastatic Colorectal Cancer","volume":"10","author":"Patel","year":"2021","journal-title":"Cancer Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.576036","article-title":"Survival Benefit of Crossover Administration of Regorafenib and Trifluridine Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer","volume":"11","author":"Chida","year":"2021","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.05.012","article-title":"Optimizing Treatment Sequence for Late-Line Metastatic Colorectal Cancer Patients Using Trifluridine\/Tipiracil and Regorafenib","volume":"17","author":"Unseld","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1634\/theoncologist.2017-0275","article-title":"Propensity Score Analysis of Regorafenib Versus Trifluridine\/Tipiracil in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study","volume":"23","author":"Moriwaki","year":"2018","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.3390\/cancers12102812","article-title":"Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy","volume":"12","author":"Huemer","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.04.002","article-title":"Real-World Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine\/Tipiracil and Regorafenib","volume":"17","author":"Patel","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.04.002","article-title":"Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib","volume":"25","author":"Patel","year":"2020","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.867546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:20:47Z","timestamp":1652937647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.867546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":21,"alternative-id":["10.3389\/fonc.2022.867546"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.867546","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"article-number":"867546"}}